Table 3.

The structures of PROTAC molecules targeting apoptosis or angiogenesis in cancers. (red: POI ligand; yellow: E3 ligand)

Target	PROTAC	PROTAC structure	Cancer	Ref	Target	PROTAC	PROTAC structure	Cancer	Ref
Bcl-xL	DT2216		T-ALL	[167]	BCR-ABL	DAS-6-2-2-6-CRBN		CML	[171]
Bcl-xL	XZ739		T-ALL	[184]	BCR-ABL	Azo-PROTAC-4C		CML	[19]
Bcl-xL	compound 8a		TL	[185]	BCR-ABL	SNIPER(ABL)-38		CML	[89]
Bcl-xL	XZ424		T-ALL	[168]	BCR-ABL	compound 19		CML	[186]
Bcl-xL	PROTAC 6		AML	[187]	BCR-ABL	GMB-475		CML	[172]
PARP1	compound 2		CRC	[188]	BCR-ABL	GMB-805		CML	[189]
PARP1	iRucaparib-AP5		CC, RCC, BC, PC	[170]	BCR-ABL	SIAIS178		CML	[190]
PARP1	compound 3		TNBC	[191]	BCR-ABL	BT1		CML	[192]
PARP1	SK-575		BC, CRC, PC, PaC	[169]	AKT	INY-03-041		BC	[173]
Bcl-2	C5		CC, CML, NSCLC	[174]	eIF4E	PROTAC 23a		TNBC, CML	[176]
Bcl-6	PROTAC 15		DLBCL	[193]	HDAC1/2/3	PROTAC 4		CRC	[194]
c-IAP	compound 6		FS	[175]	HDAC1/2/3	XZ9002		TNBC	[195]
CK2	PROTAC 2		TNBC, NSCLC	[196]	HDAC6	PROTAC 4		OSCC, GB	[197]
CRABP I/II	compound 4b		NB	[8]	HDAC6	degrader 12d		MM	[198]
CRABP I/II	compound 6		FS	[175]	HDAC6	NP8		MM, CC	[199]
CRABP I/II	β-NF-ATRA		BC, NB	[140]	HDAC6	NH2		MM, CC	[200]
eEF2K	compound 11l		BC	[201]	HDAC6	P1		MM	[202]
HDAC6	compound 3j		MM	[203]	CBP/ p300	dCBP-1		MM	[181]
Mcl-1	dMCL1-2		MM	[177]	RIPK2	PROTAC_RIPK2		BC, AML	[17]
Mcl-1	C3		CC, CML, NSCLC	[174]	SGK3	SGK3-PROTAC1		BC	[204]
MDM2	MD-224		ALL, AML	[179]	SirT2	PROTAC 12		CC	[182]
MDM2	degrader 32		ALL	[178]	VEGFR2	PROTAC-5		/	[183]
PI3K	compound D		HCC	[180]